298 related articles for article (PubMed ID: 34249700)
1. Epigenetics in the Pathogenesis and Treatment of Cutaneous T-Cell Lymphoma.
Zhang P; Zhang M
Front Oncol; 2021; 11():663961. PubMed ID: 34249700
[TBL] [Abstract][Full Text] [Related]
2. Novel cell adhesion/migration pathways are predictive markers of HDAC inhibitor resistance in cutaneous T cell lymphoma.
Andrews JM; Schmidt JA; Carson KR; Musiek AC; Mehta-Shah N; Payton JE
EBioMedicine; 2019 Aug; 46():170-183. PubMed ID: 31358475
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics of cutaneous T-cell lymphoma: biomarkers and therapeutic potentials.
Lai P; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):34-51. PubMed ID: 33628583
[TBL] [Abstract][Full Text] [Related]
4. MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas.
Gluud M; Willerslev-Olsen A; Gjerdrum LMR; Lindahl LM; Buus TB; Andersen MH; Bonefeld CM; Krejsgaard T; Litvinov IV; Iversen L; Becker JC; Persson JL; Koralov SB; Litman T; Geisler C; Woetmann A; Odum N
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32414221
[TBL] [Abstract][Full Text] [Related]
5. Current Status of HDAC Inhibitors in Cutaneous T-cell Lymphoma.
Lopez AT; Bates S; Geskin L
Am J Clin Dermatol; 2018 Dec; 19(6):805-819. PubMed ID: 30173294
[TBL] [Abstract][Full Text] [Related]
6. Molecular pathogenesis of Cutaneous T cell Lymphoma: Role of chemokines, cytokines, and dysregulated signaling pathways.
Patil K; Kuttikrishnan S; Khan AQ; Ahmad F; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cancer Biol; 2022 Nov; 86(Pt 3):382-399. PubMed ID: 34906723
[TBL] [Abstract][Full Text] [Related]
7. BCL11B-Mediated Epigenetic Repression Is a Crucial Target for Histone Deacetylase Inhibitors in Cutaneous T-Cell Lymphoma.
Fu W; Yi S; Qiu L; Sun J; Tu P; Wang Y
J Invest Dermatol; 2017 Jul; 137(7):1523-1532. PubMed ID: 28288848
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic therapy and dermatologic disease: moving beyond CTCL.
Mervis JS; McGee JS
J Dermatolog Treat; 2019 Feb; 30(1):68-73. PubMed ID: 29726727
[TBL] [Abstract][Full Text] [Related]
9. Single-Cell Heterogeneity of Cutaneous T-Cell Lymphomas Revealed Using RNA-Seq Technologies.
Rassek K; Iżykowska K
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32751918
[TBL] [Abstract][Full Text] [Related]
10. The cross-talk between miRNAs and JAK/STAT pathway in cutaneous T cell lymphoma: Emphasis on therapeutic opportunities.
Patil K; Sher G; Kuttikrishnan S; Moton S; Alam M; Buddenkotte J; Ahmad A; Steinhoff M; Uddin S
Semin Cell Dev Biol; 2024 Feb; 154(Pt C):239-249. PubMed ID: 36216715
[TBL] [Abstract][Full Text] [Related]
11. Update on Biology of Cutaneous T-Cell Lymphoma.
Phyo ZH; Shanbhag S; Rozati S
Front Oncol; 2020; 10():765. PubMed ID: 32477957
[TBL] [Abstract][Full Text] [Related]
12. DOT1L inhibition does not modify the sensitivity of cutaneous T cell lymphoma to pan-HDAC inhibitors
Kwesi-Maliepaard EM; Malik M; van Welsem T; van Doorn R; Vermeer MH; Vlaming H; Jacobs H; van Leeuwen F
Front Genet; 2022; 13():1032958. PubMed ID: 36425063
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-16 mediates the regulation of a senescence-apoptosis switch in cutaneous T-cell and other non-Hodgkin lymphomas.
Kitadate A; Ikeda S; Teshima K; Ito M; Toyota I; Hasunuma N; Takahashi N; Miyagaki T; Sugaya M; Tagawa H
Oncogene; 2016 Jul; 35(28):3692-704. PubMed ID: 26640145
[TBL] [Abstract][Full Text] [Related]
14. Genetic and epigenetic insights into cutaneous T-cell lymphoma.
Tensen CP; Quint KD; Vermeer MH
Blood; 2022 Jan; 139(1):15-33. PubMed ID: 34570882
[TBL] [Abstract][Full Text] [Related]
15. Advances in the understanding and treatment of Cutaneous T-cell Lymphoma.
Bakr FS; Whittaker SJ
Front Oncol; 2022; 12():1043254. PubMed ID: 36505788
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic profiling of cutaneous T-cell lymphoma: promoter hypermethylation of multiple tumor suppressor genes including BCL7a, PTPRG, and p73.
van Doorn R; Zoutman WH; Dijkman R; de Menezes RX; Commandeur S; Mulder AA; van der Velden PA; Vermeer MH; Willemze R; Yan PS; Huang TH; Tensen CP
J Clin Oncol; 2005 Jun; 23(17):3886-96. PubMed ID: 15897551
[TBL] [Abstract][Full Text] [Related]
17. Comparison of DNA demethylating and histone deacetylase inhibitors hydralazine-valproate versus vorinostat-decitabine incutaneous t-cell lymphoma in HUT78 cells.
Schcolnik-Cabrera A; Domínguez-Gómez G; Dueñas-González A
Am J Blood Res; 2018; 8(2):5-16. PubMed ID: 30038842
[TBL] [Abstract][Full Text] [Related]
18. Primary cutaneous T-cell lymphoma: review and current concepts.
Siegel RS; Pandolfino T; Guitart J; Rosen S; Kuzel TM
J Clin Oncol; 2000 Aug; 18(15):2908-25. PubMed ID: 10920140
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors inhibit metastasis by restoring a tumor suppressive microRNA-150 in advanced cutaneous T-cell lymphoma.
Abe F; Kitadate A; Ikeda S; Yamashita J; Nakanishi H; Takahashi N; Asaka C; Teshima K; Miyagaki T; Sugaya M; Tagawa H
Oncotarget; 2017 Jan; 8(5):7572-7585. PubMed ID: 27935859
[TBL] [Abstract][Full Text] [Related]
20. Targeting histone deacetylases in T-cell lymphoma.
Moskowitz AJ; Horwitz SM
Leuk Lymphoma; 2017 Jun; 58(6):1306-1319. PubMed ID: 27813438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
